176 related articles for article (PubMed ID: 23567624)
21. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
Mangold AR; Bryce A; Sekulic A
J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
[No Abstract] [Full Text] [Related]
22. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
23. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
[No Abstract] [Full Text] [Related]
24. Second primary melanomas on treatment with vemurafenib.
Dalle S; Poulalhon N; Debarbieux S; Thomas L
Br J Dermatol; 2013 Apr; 168(4):887-8. PubMed ID: 23066856
[No Abstract] [Full Text] [Related]
25. Vemurafenib-induced hypertension: is it real?
Balakan O; Babacan T; Altundag K
J BUON; 2013; 18(2):545. PubMed ID: 23818377
[No Abstract] [Full Text] [Related]
26. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
Degen A; Völker B; Kapp A; Gutzmer R
Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
[No Abstract] [Full Text] [Related]
27. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
[No Abstract] [Full Text] [Related]
28. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib.
Finelt N; Lulla RR; Melin-Aldana H; Ruth JS; Lin FY; Su JM; Pourciau CY; Hunt RD; Kenner-Bell BM
Pediatr Dermatol; 2017 May; 34(3):337-341. PubMed ID: 28523881
[TBL] [Abstract][Full Text] [Related]
29. Acne inversa-like skin lesions as a potential adverse event during vemurafenib therapy.
Thiem A; Mergler R; Kneitz H; Weyandt G; Goebeler M; Gesierich A
J Dtsch Dermatol Ges; 2016 Apr; 14(4):427-8. PubMed ID: 27027759
[No Abstract] [Full Text] [Related]
30. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
Kim GH; Levy A; Compoginis G
J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
[TBL] [Abstract][Full Text] [Related]
31. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
32. Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.
Wakimoto H; Harada K; Arai T; Maeda T; Irisawa R; Tsuboi R
Int J Dermatol; 2017 Feb; 56(2):e33-e35. PubMed ID: 27805257
[No Abstract] [Full Text] [Related]
33. Delayed oral toxicity from long-term vemurafenib therapy.
Lloyd-Lavery A; Hodgson T; Coupe N; Bond S; Shah K; Espinosa O; Payne MJ; Middleton MR; Matin RN
Br J Dermatol; 2016 May; 174(5):1159-60. PubMed ID: 26853702
[No Abstract] [Full Text] [Related]
34. Vemurafenib-induced DRESS.
Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
[No Abstract] [Full Text] [Related]
35. Fanconi syndrome induced by vemurafenib: a new renal adverse event.
Denis D; Franck N; Fichel F; Levi C; Dupin N
JAMA Dermatol; 2015 Apr; 151(4):453-4. PubMed ID: 25494458
[No Abstract] [Full Text] [Related]
36. Second primary melanomas on treatment with vemurafenib: reply from the authors.
Fearfield L; Newton-Bishop JA; Sinha R; Edmonds K; Gore ME; Larkin J
Br J Dermatol; 2013 Apr; 168(4):888-9. PubMed ID: 23066884
[No Abstract] [Full Text] [Related]
37. Uveitic macular oedema after treatment with vemurafenib.
Fonollosa A; Mesquida M; Adan A
Acta Ophthalmol; 2015 Dec; 93(8):e686-7. PubMed ID: 25683228
[No Abstract] [Full Text] [Related]
38. Successful treatment of multiple vemurafenib-induced keratoacanthomas by topical application of imiquimod cream: Confirmation of clinical clearance by dermoscopy.
Rhee do Y; Won KH; Lee YJ; Won CH; Chang SE; Lee MW
J Dermatolog Treat; 2016 Oct; 27(5):448-9. PubMed ID: 27092864
[TBL] [Abstract][Full Text] [Related]
39. Panniculitis in patients treated with BRAF inhibitors: a case series.
Choy B; Chou S; Anforth R; Fernández-Peñas P
Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
[TBL] [Abstract][Full Text] [Related]
40. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
Pattanaprichakul P; Tetzlaff MT; Lapolla WJ; Torres-Cabala CA; Duvic M; Prieto VG; Tsai KY; Curry JL
J Cutan Pathol; 2014 Mar; 41(3):326-8. PubMed ID: 24372055
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]